The Sanger (UK) and Broad (USA) Institutes joined efforts to generate a complete map of all cancer vulnerabilities to propose novel therapeutical targets (Cancer Dependency Map).
Harnessing the Cancer DepMap CRISPR-Cas9 and drug sensitivity screens across 484 cancer cell lines, we created a computational resource for 397 anti-cancer drugs that informs on many aspects of drug mode-of-action (i.e. in cellular activity, isoform specificity and potential polypharmacology effects).
The millions of associations tested allowed us to characterise protein networks underlying drug response and revealed novel regulatory interactions.
This Study Was Featured
Gonçalves, Emanuel, Aldo Segura-Cabrera, Clare Pacini, Gabriele Picco, Fiona M. Behan, Patricia Jaaks, Elizabeth A. Coker, et al. 2020. “Drug Mechanism-of-Action Discovery through the Integration of Pharmacological and CRISPR Screens.” Molecular Systems Biology 16 (7): e9405.